Chief Medical Officer · DICE Therapeutics, Inc. (DICE)

Timothy Lu

A named executive officer of DICE Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,722,088

Salary $450,000Stock awards $0

FY2021: $2,038,779

2nd of 3 named executive officers at Dice Therapeutics by FY2022 total.

3 named officers on file for DICE Therapeutics, FY2022

Timothy Lu’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how DICE Therapeutics’s whole pay program stands against its peers

  • DICE Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DICE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2023 (DEF 14A).

Free

Get Timothy Lu’s full pay file as a PDF — free

More than this page: up to 10 years of Timothy’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Timothy Lu compensation by year

DICE Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as DICE Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$410,438$450,000
Bonus$50,000$0
Stock awards$314,412$0
Option awards$1,063,929$2,022,088
Non-equity incentive$200,000$250,000
Pension and deferred compensation$0$0
All other$0$0
Total$2,038,779$2,722,088

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: DICE Therapeutics, Inc. DEF 14A filed April 26, 2023, accession 0000950170-23-014782, and prior-year filings. Open the filing on EDGAR.

How this page was built: the DICE Therapeutics, Inc. filed document, accession 0000950170-23-014782. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.

$2.0M
$2.7M
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awards

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU41,509$1,295,081—
RSU32,637$1,018,274—
Option13,044—$17.00
Option42,108—$17.00
Option121,604—$19.64

Per the Outstanding Equity Awards at Fiscal Year-End table in DICE Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

DICE Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
J. Kevin JudiceChief Executive Officer$5,773,577
Timothy Lu · this pageChief Medical Officer$2,722,088
Scott RobertsonChief Business and Financial Officer$2,667,149

The full DICE Therapeutics compensation record

free company brief

This page is one person within DICE Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are DICE Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Timothy Lu's compensation dossier · One-time report. No refunds.